| 摘要 |
The present invention relates to a compound of formula (I); wherein R<1 >represents isopropyl or trifluoromethyl; R<2 >represents hydrogen, C1-4alkyl, chloro, fluoro or trifluoromethyl; R<3 >represents(i) phenyl, optionally substituted by cyano, halogen, trifluoromethyl or an optionally substituted 5-membered heteroaromatic group, where optional substitution is effected by C1-4alkyl, (ii) a 5-membered heteroaromatic group, optionally substituted by halogen, cyano or C1-4alkyl, (ii) aminocabonyl, or(iv) ethyl or eth-1-enyl; R<4 >represents cyano, methyl, acetyl, a 5-membered heteoaromatic group, optionally substituted by C1-4alkyl or phenyl or a group X-Y-Z; X represents a carboxy, oxo, C1-6alkylene, carboxamido or thiocarboxamido linking group; Y represents a direct link or C1-4alkylene, Z represents (i) hydrogen, (ii) trifluoromethyl, (iii) cyano, (iv) phenyl (v) a 5- or 6-membered heteroaromatic group, optionally substituted by C1-4alkyl, with the proviso that when X represents C1-4alkylene, Y and Z do not represent a direct link and hydrogen respectively, or when X represents oxo, Y and Z do not represent C1-6alkylene and hydrogen respectively; or a physiologically acceptable salt, solvate or derivative thereof, to compositions comprising the compound, processes for their preparation and their use in treating conditions ameliorated by an apoB-100 and/or MTP inhibitor.
|
